Literature DB >> 19490465

Classification of follicular cell tumors of the thyroid gland: analysis involving Japanese patients from one institute.

Kennichi Kakudo1, Yanhua Bai, Shoichi Katayama, Mitsuyoshi Hirokawa, Yasuhiro Ito, Akira Miyauchi, Kanji Kuma.   

Abstract

Prognostic analyses of thyroid carcinomas of follicular cell origin were carried out on patients treated at Kuma Hospital, Kobe, Japan. A new histopathological classification based on the prognostic evidence is proposed in this study, and it is applicable to the patients treated curatively. Major histological types of papillary carcinoma, follicular carcinoma and poorly differentiated carcinoma were combined into one single entity of follicular cell adenocarcinoma because (i) they have the same cell origin (follicular cell); (ii) clear-cut separation of papillary and follicular carcinoma is not always possible, and 10 year cause-specific survival was essentially similar when the patients were treated curatively; and (iii) poorly differentiated carcinoma usually has a background of either papillary or follicular carcinoma. This adenocarcinoma together with undifferentiated carcinoma was stratified into four prognostic groups using pure morphological criteria of the degree of cellular differentiation and histological grade. They are termed well-differentiated adenocarcinoma, moderately differentiated adenocarcinoma, poorly differentiated carcinoma and undifferentiated carcinoma of the thyroid. The 10 year disease-free survival rates were 86.3-93.1%, 65.4-78.7%, and 43.0-53.8%, and 0%, respectively. The 10 year cause-specific survival rates were 97.2-100%, 91.5-97.4%, and 71.2-80.0%, and 0%, respectively.

Entities:  

Mesh:

Year:  2009        PMID: 19490465     DOI: 10.1111/j.1440-1827.2009.02378.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  10 in total

Review 1.  Papillary carcinoma tall cell variant (TCV): a review.

Authors:  Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

2.  Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful?

Authors:  Tihana Ibrahimpasic; Ronald Ghossein; Diane L Carlson; Iain J Nixon; Frank L Palmer; Snehal G Patel; Robert M Tuttle; Ashok Shaha; Jatin P Shah; Ian Ganly
Journal:  Ann Surg Oncol       Date:  2015-04-17       Impact factor: 5.344

3.  Emerin expression in well differentiated epithelial lesions of thyroid: implications in papillary thyroid carcinoma diagnosis and predicting malignant behavior.

Authors:  Ipek Coban; Asli Cakir; Tuba Dilay Kokenek Unal; Nuray Bassullu; Vildan Karpuz; Gulen Bulbul Dogusoy; Murat Alper
Journal:  Pathol Oncol Res       Date:  2014-08-14       Impact factor: 3.201

4.  Alterations of tumor-related genes do not exactly match the histopathological grade in gastric adenocarcinomas.

Authors:  Guo-Yan Liu; Kun-Hong Liu; Yong Zhang; Yu-Zhi Wang; Xiao-Hong Wu; Yi-Zhuo Lu; Chao Pan; Ping Yin; Hong-Feng Liao; Ji-Qin Su; Qing Ge; Qi Luo; Bin Xiong
Journal:  World J Gastroenterol       Date:  2010-03-07       Impact factor: 5.742

Review 5.  How to handle borderline/precursor thyroid tumors in management of patients with thyroid nodules.

Authors:  Kennichi Kakudo
Journal:  Gland Surg       Date:  2018-08

Review 6.  Aggressive variants of follicular cell-derived thyroid carcinoma: an overview.

Authors:  Cristina Pizzimenti; Vincenzo Fiorentino; Antonio Ieni; Maurizio Martini; Giovanni Tuccari; Maria Lentini; Guido Fadda
Journal:  Endocrine       Date:  2022-07-21       Impact factor: 3.925

7.  PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.

Authors:  Matthew W Rosenbaum; Benjamin J Gigliotti; Sara I Pai; Sareh Parangi; Heather Wachtel; Mari Mino-Kenudson; Viswanath Gunda; William C Faquin
Journal:  Endocr Pathol       Date:  2018-03       Impact factor: 3.943

8.  Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study.

Authors:  Lin Cheng; Hao Fu; Yuchen Jin; Ri Sa; Libo Chen
Journal:  Oncologist       Date:  2020-01-20

9.  Application of intensity-modulated radiotherapy in unresectable poorly differentiated thyroid carcinoma.

Authors:  Fen Xue; Duanshu Li; Chaosu Hu; Zhuoying Wang; Xiayun He; Yi Wu
Journal:  Oncotarget       Date:  2017-02-28

10.  Histopathology and immunohistochemistry as prognostic factors for poorly differentiated thyroid cancer in a series of Polish patients.

Authors:  Agnieszka Walczyk; Janusz Kopczyński; Danuta Gąsior-Perczak; Iwona Pałyga; Artur Kowalik; Magdalena Chrapek; Maria Hejnold; Stanisław Góźdź; Aldona Kowalska
Journal:  PLoS One       Date:  2020-02-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.